Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122052932 | 12205293 | 2 | F | 20160317 | 20160907 | 20160323 | 20160914 | PER | PHEH2016US007013 | NOVARTIS | 45.69 | YR | F | Y | 0.00000 | 20160914 | CN | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122052932 | 12205293 | 1 | PS | GILENYA | FINGOLIMOD HYDROCHLORIDE | 1 | Oral | 0.5 MG, QD | 22527 | .5 | MG | QD | |||||||
| 122052932 | 12205293 | 2 | C | LORAZEPAM. | LORAZEPAM | 1 | Unknown | UNK | U | 0 | |||||||||
| 122052932 | 12205293 | 3 | C | ABILIFY | ARIPIPRAZOLE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122052932 | 12205293 | 1 | Multiple sclerosis |
| 122052932 | 12205293 | 2 | Product used for unknown indication |
| 122052932 | 12205293 | 3 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122052932 | 12205293 | Fatigue | |
| 122052932 | 12205293 | Heart rate decreased | |
| 122052932 | 12205293 | Somnolence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122052932 | 12205293 | 1 | 20160317 | 0 |